Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With CancerNobuyuki Katakami, Narikazu Boku, Katsunori Shinozaki et al.|Journal of Clinical Oncology|2017Cited by 64
A phase II randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain.Narikazu Boku, Masaru Narabayashi, Nobuyuki Katakami et al.|Journal of Clinical Oncology|2015Cited by 1